Alvotech (ALVO) Q1 2023: Revenue Jumps 16x on Biosimilar Launches, U.S. Approval Uncertainty Persists
Alvotech’s first quarter saw a dramatic revenue surge from global biosimilar launches, but U.S. market entry for its Humira biosimilar remains stalled by FDA site inspection issues. The company’s pipeline expansion and commercial partnerships broadened its global reach, yet near-term financial guidance and liquidity hinge on regulatory clarity. Investors face a critical inflection point as Alvotech navigates both operational scale-up and regulatory hurdles in the world’s largest biologics market.
Summary
- Regulatory Bottleneck Remains Central: U.S. Humira biosimilar approval is delayed pending FDA resolution.
- Commercial Model Scales Globally: Revenue sharing and new launches drive steep top-line growth outside the U.S.
- Liquidity and Guidance Linked to FDA Outcome: Future capital needs and financial outlook depend on regulatory timing.
Business Overview
Alvotech is a pure-play biosimilar company—it develops, manufactures, and commercializes biosimilar medicines, which are highly similar versions of approved biologic drugs. The business operates a B2B model, generating revenue through milestone payments and ongoing revenue sharing (approximately 40% of net sales) with commercial partners. Its core portfolio targets immunology and oncology, with major candidates including biosimilars to Humira, Stelara, Entyvio, and Keytruda, spanning over 90 global markets through 18 partner relationships.
Performance Analysis
Alvotech delivered a step-change in revenue, reporting $16 million for Q1 2023 compared to just $1 million a year ago. This surge reflects the commercial ramp of AVT02, its Humira biosimilar, across Canada and Europe, as well as expansion into 70 global markets. However, no milestone revenue was recognized in the quarter, with management flagging that most licensing and milestone payments are weighted to the second half of the year as launches mature and performance triggers are met.
Gross margin remains under pressure, as cost of product revenue exceeded product sales due to the timing of new launches and elevated production charges. This imbalance is expected to normalize as manufacturing scale increases, fixed costs are absorbed, and more markets come online. Alvotech ended the quarter with $116 million in cash (excluding $25 million restricted), but with U.S. launch timing uncertain, the company is exploring further capital raises to support ongoing R&D and commercial expansion.
- Revenue Spike Driven by Global Launches: AVT02 launches outside the U.S. accelerated revenue, but milestone payments are back-half loaded.
- Cost Structure Temporarily Unbalanced: Elevated production costs and inventory build created negative gross margin, expected to recover with scale.
- Liquidity Actions Underway: Recent private placement and convertible bond proceeds shore up cash, but additional funding may be needed if U.S. approval is delayed.
The company’s ability to convert pipeline progress into sustainable profitability will depend on resolving regulatory bottlenecks and achieving greater manufacturing efficiency as volumes ramp.
Executive Commentary
"Both BLA have been reviewed and are deemed approvable, with the only outstanding requirement being a satisfactory site inspection... We continue to supply other markets. We have launched AVT02 into 70 markets, including Canada and across Europe, without any negative safety signal to date."
Robert Westman, Chairman and Chief Executive Officer
"Cost of product revenue for the quarter is disproportionate relative to product revenue due to the timing of new launches and elevated production-related charges... We do expect this to normalize as we increase scale of manufacturing and expand our launches."
Joel Morales, Chief Financial Officer
Strategic Positioning
1. U.S. Regulatory Pathway: Humira Biosimilar Approval in Focus
The U.S. AVT02 approval remains the single largest swing factor for Alvotech’s growth trajectory. Both biosimilar and interchangeable BLAs are considered approvable by the FDA, but final clearance is contingent on resolving site inspection findings and potential re-inspection. The company is actively engaging with the FDA and providing monthly updates, but admits that launch timing is entirely dependent on regulatory feedback, with a June 28 target for the interchangeable BLA and a possible six-month review clock if resubmission is required.
2. Pipeline Expansion and Diversification
Alvotech is broadening its portfolio with new biosimilar candidates for Entyvio (AVT16) and Keytruda (AVT33), entering immunology and oncology markets with multi-billion-dollar addressable opportunities. The company’s R&D engine remains active, with five products at the patient study stage and additional undisclosed candidates in early development.
3. Commercial Model and Global Partner Network
The B2B model underpins scalability and risk-sharing, leveraging 18 partners across 90+ markets. This approach provides upfront milestone payments and recurring revenue sharing, allowing Alvotech to focus on development and manufacturing while partners handle local commercialization. Ongoing launches and pricing negotiations in Europe, Canada, and other regions are expected to drive revenue growth as regulatory approvals are secured.
4. Manufacturing Scale and Cost Absorption
Operational leverage is a key focus, as increased production volumes are expected to improve gross margin by absorbing fixed manufacturing costs. Inventory build in anticipation of launches is temporarily inflating costs, but management expects normalization as sales ramp and launches accelerate in the second half of 2023.
5. ESG and Healthcare Sustainability Narrative
Alvotech positions biosimilars as a solution for global healthcare sustainability, highlighting recent ESG disclosures and the societal value of affordable biologics. The company’s narrative aligns with long-term policy trends favoring cost-effective access to essential medicines.
Key Considerations
This quarter underscores a pivotal period for Alvotech, as its global commercial execution advances but the U.S. regulatory timeline remains opaque. Investors must weigh the operational momentum against the binary risk of FDA approval.
Key Considerations:
- Regulatory Timing Dominates Near-Term Outlook: The U.S. launch for AVT02 is the largest value unlock, but is hostage to FDA site inspection resolution.
- Pipeline Breadth Expands Future Optionality: New immunology and oncology assets target large, growing markets, increasing long-term revenue potential.
- Cash Burn and Funding Needs: Delayed U.S. entry could necessitate further capital raises, diluting existing shareholders if not managed proactively.
- Commercial Partnerships Mitigate Regional Risk: The B2B model provides diversification and leverages local expertise, but also reduces direct control over market execution.
Risks
Alvotech faces acute regulatory risk, with U.S. Humira biosimilar approval hinging on timely and satisfactory FDA resolution of manufacturing site issues. Prolonged delays could impair liquidity, force additional dilutive financing, and defer commercial milestones. Further, competition in biosimilars is intensifying, and the company’s reliance on partners introduces execution variability across markets. Macroeconomic factors and evolving regulatory frameworks for biosimilars in major markets present additional uncertainty.
Forward Outlook
For Q2 2023, Alvotech guided to:
- Continued expansion of AVT02 launches in ex-U.S. markets.
- Increased shipments to commercial partners, with milestone revenue expected to be recognized in the second half of the year.
For full-year 2023, management did not provide formal guidance, citing:
- Pending clarity on FDA approval timing for AVT02 in the U.S. and impact on commercial contracting.
Management emphasized that liquidity planning and operational scale are being dynamically managed to align with regulatory outcomes and market launch timing.
- FDA meeting and site inspection resolution are the gating factors for U.S. launch.
- Additional capital raising is under consideration depending on approval timing.
Takeaways
Alvotech’s quarter is a study in global execution amid regulatory uncertainty.
- Revenue Acceleration Outside U.S.: Global launches validate the commercial model and pipeline, but profitability is deferred until scale and U.S. access are achieved.
- U.S. Approval Remains the Decisive Catalyst: The timing and outcome of FDA site inspection findings will dictate near-term valuation and liquidity needs.
- Pipeline and Partner Model Build Long-Term Value: Ongoing R&D and new commercial agreements broaden future optionality, but do not offset near-term binary risk around AVT02.
Conclusion
Alvotech’s Q1 2023 results highlight a rapidly scaling global biosimilar platform, but the company’s near-term fate is closely tied to U.S. regulatory approval for its Humira biosimilar. While commercial traction and pipeline expansion are clear positives, investors must monitor FDA developments and liquidity actions as the critical drivers of future performance.
Industry Read-Through
Alvotech’s experience underscores the centrality of regulatory risk in the biosimilars sector, especially for U.S. market entry where site inspection findings can delay even technically approvable products. The B2B, milestone-heavy revenue model is gaining traction among biosimilar developers seeking to balance risk and capital intensity. Manufacturing scale and operational excellence remain key differentiators as competition intensifies and payers drive price pressure. For other players, early regulatory engagement and robust quality systems are essential to avoid costly delays, while diversified pipelines and global partnerships can mitigate regional risk. The industry’s long-term growth, however, remains anchored in the expanding adoption of biosimilars to address healthcare cost pressures worldwide.